标题
The role of immunotherapy in small cell lung cancer
作者
关键词
Lung cancer, Immunotherapy, Immune-checkpoint inhibitors, Cancer vaccines, PD-1, PD-L1, CTLA-4
出版物
Clinical & Translational Oncology
Volume -, Issue -, Pages -
出版商
Springer Nature
发表日期
2019-01-12
DOI
10.1007/s12094-018-02011-9
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer
- (2018) Matthew D. Hellmann et al. CANCER CELL
- Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC)
- (2018) Shirish M. Gadgeel et al. Journal of Thoracic Oncology
- Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158.
- (2018) Hyun Cheol Chung et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of rovalpituzumab tesirine in patients With DLL3-expressing, ≥ 3rd line small cell lung cancer: Results from the phase 2 TRINITY study.
- (2018) David Paul Carbone et al. JOURNAL OF CLINICAL ONCOLOGY
- First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
- (2018) Leora Horn et al. NEW ENGLAND JOURNAL OF MEDICINE
- 1664OA randomized non-comparative phase II study of anti–PD-L1 ATEZOLIZUMAB or chemotherapy as second-line therapy in patients with small cell lung cancer: Results from the IFCT-1603 trial
- (2018) J-L Pujol et al. ANNALS OF ONCOLOGY
- Cancer immunotherapy targeting the CD47/SIRPα axis
- (2017) Kipp Weiskopf EUROPEAN JOURNAL OF CANCER
- Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study
- (2017) Patrick A. Ott et al. JOURNAL OF CLINICAL ONCOLOGY
- P1.15-004 An Open-Label, Multitumor Phase II Basket Study of Olaparib and Durvalumab (MEDIOLA): Results in Patients with Relapsed SCLC
- (2017) M. Krebs et al. Journal of Thoracic Oncology
- P2.04-002 CASPIAN: Phase 3 Study of First-Line Durvalumab ± Tremelimumab + Platinum-Based Chemotherapy vs Chemotherapy Alone in ED-SCLC
- (2017) L. Paz-Ares et al. Journal of Thoracic Oncology
- Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study
- (2017) Charles M Rudin et al. LANCET ONCOLOGY
- MHC class II expression in lung cancer
- (2017) Yayi He et al. LUNG CANCER
- Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
- (2017) Aaron M. Goodman et al. MOLECULAR CANCER THERAPEUTICS
- Unravelling the biology of SCLC: implications for therapy
- (2017) Joshua K. Sabari et al. Nature Reviews Clinical Oncology
- A prospective pilot study of genome-wide exome and transcriptome profiling in patients with small cell lung cancer progressing after first-line therapy
- (2017) Glen J. Weiss et al. PLoS One
- Neoantigens Generated by Individual Mutations and Their Role in Cancer Immunity and Immunotherapy
- (2017) Mirjana Efremova et al. Frontiers in Immunology
- Clinical activity, safety and predictive biomarkers results from a phase Ia atezolizumab (atezo) trial in extensive-stage small cell lung cancer (ES-SCLC)
- (2016) L.V. Sequist et al. ANNALS OF ONCOLOGY
- A phase 1/2 trial of a monoclonal antibody targeting fucosyl GM1 in relapsed/refractory small cell lung cancer (SCLC): Safety and preliminary efficacy
- (2016) Q.S-C. Chu et al. ANNALS OF ONCOLOGY
- A Phase III study of atezolizumab with carboplatin plus etoposide in patients with extensive-stage small cell lung cancer (IMpower133)
- (2016) L. Horn et al. ANNALS OF ONCOLOGY
- STIMULI: A randomised open-label phase II trial of consolidation with nivolumab and ipilimumab in limited-stage SCLC after standard of care chemo-radiotherapy conducted by ETOP and IFCT
- (2016) D. De Ruysscher et al. ANNALS OF ONCOLOGY
- Microsatellite Instability as a Biomarker for PD-1 Blockade
- (2016) J. C. Dudley et al. CLINICAL CANCER RESEARCH
- CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer
- (2016) Kipp Weiskopf et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer
- (2016) Martin Reck et al. JOURNAL OF CLINICAL ONCOLOGY
- Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC
- (2016) Edurne Arriola et al. Journal of Thoracic Oncology
- Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
- (2016) Scott J Antonia et al. LANCET ONCOLOGY
- Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?
- (2015) L. Apetoh et al. ANNALS OF ONCOLOGY
- Dinutuximab: First Global Approval
- (2015) Sohita Dhillon DRUGS
- Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline
- (2015) Charles M. Rudin et al. JOURNAL OF CLINICAL ONCOLOGY
- Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer
- (2015) Hidenobu Ishii et al. Journal of Thoracic Oncology
- Comprehensive genomic profiles of small cell lung cancer
- (2015) Julie George et al. NATURE
- A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo
- (2015) Laura R. Saunders et al. Science Translational Medicine
- Design and Structural Requirements of the Potent and Safe TLR-9 Agonistic Immunomodulator MGN1703
- (2015) Manuel Schmidt et al. Nucleic Acid Therapeutics
- Interferon alpha plus 13-cis-retinoic acid modulation of BCL-2 plus paclitaxel for recurrent small-cell lung cancer (SCLC): an Eastern Cooperative Oncology Group study (E6501)
- (2014) Rathi N. Pillai et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2013) M. Fruh et al. ANNALS OF ONCOLOGY
- Histologic Assessment of Tumor-Associated CD45 + Cell Numbers Is an Independent Predictor of Prognosis in Small Cell Lung Cancer
- (2013) Wei Wang et al. CHEST
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- Rationale for Chemotherapy, Immunotherapy, and Checkpoint Blockade in SCLC: Beyond Traditional Treatment Approaches
- (2013) David R. Spigel et al. Journal of Thoracic Oncology
- Immunomodifiers in combination with conventional chemotherapy in small cell lung cancer: a Phase II, randomized study
- (2013) Paul Zarogoulidis et al. Drug Design Development and Therapy
- Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial†
- (2012) M. Reck et al. ANNALS OF ONCOLOGY
- Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer
- (2012) Martin Peifer et al. NATURE GENETICS
- The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors
- (2012) S. B. Willingham et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Immunization with N-propionyl polysialic acid–KLH conjugate in patients with small cell lung cancer is safe and induces IgM antibodies reactive with SCLC cells and bactericidal against group B meningococci
- (2011) Lee M. Krug et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Cancer immunotherapy comes of age
- (2011) Ira Mellman et al. NATURE
- SEOM clinical guidelines for the treatment of small-cell lung cancer
- (2010) Ángel Artal Cortés et al. Clinical & Translational Oncology
- Treatment of high-risk neuroblastoma with anti-GD2 antibodies
- (2010) Victoria Castel et al. Clinical & Translational Oncology
- Anti-GD2 Antibody Therapy for GD2-Expressing Tumors
- (2010) F. Navid et al. CURRENT CANCER DRUG TARGETS
- INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect
- (2010) Alberto A Chiappori et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- Reciprocal CD4+ T-Cell Balance of Effector CD62Llow CD4+ and CD62LhighCD25+ CD4+ Regulatory T Cells in Small Cell Lung Cancer Reflects Disease Stage
- (2008) K. Koyama et al. CLINICAL CANCER RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now